| ²é¿´: 122 | »Ø¸´: 0 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
lixingkeר¼Ò¹ËÎÊ
|
[½»Á÷]
Ò©Æ·Ó¢ÎÄ˵Ã÷Êé·ÒëÓм¸¸öרҵ´Ê»ã²»¶®
|
||
|
1.General disorders and administration site conditions 2.In the event of bradycardia with poor haemodynamic tolerance ÄÇλ¸ßÊÖ¸ø·Òëһϣ¬Ð»Ð»ÁË |
» ²ÂÄãϲ»¶
×î½üFrontier in EndocrinologyÓиö¾«×ÓÑо¿Ïà¹ØµÄÖ÷Ìâר¿¯£¬ÓкÏÊʸå¼þ¿É¹Ø×¢¡£
ÒѾÓÐ1È˻ظ´
ÂÛÎÄͶ¸å±»¾Ü£¬Ïëargue£¬¸÷λ´óÉñÓÐÏà¹Ø¾Ñéô
ÒѾÓÐ16È˻ظ´
Ö×ÁöѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ57È˻ظ´
¶ÔÓÚÎÄÕÂÀïÃæÒýÓñðÈËоƬÊý¾ÝµÄÏà¹ØÎÊÌâ
ÒѾÓÐ5È˻ظ´
ҽѧÀàsciÈýÉ󽫽ü2¸öÔÂÁË»¹ÔÚpeer review
ÒѾÓÐ7È˻ظ´
ÕâÖÖÇé¿ö½¨Òé´ß¸åÂð£¿
ÒѾÓÐ3È˻ظ´
µÚÒ»´ÎsciͶ¸å£¬´óÐÞºóСÐÞ£¬ÏÂÃæÊÇÉó¸åÈ˵ÄÒâ¼û£¬½ÓÊÕ¸ÅÂÊÓжà´ó?
ÒѾÓÐ12È˻ظ´
sciÂÛÎÄСÐÞ±à¼Ã»¸øÉó¸åÒâ¼û£¡
ÒѾÓÐ13È˻ظ´
ÁÙ´²Ò½Ñ§¸´ÊÔµ÷¼Á Ò»Ö¾Ô¸ÎÂÖÝÒ½¿Æ´óѧ 321·Ö
ÒѾÓÐ0È˻ظ´
Î÷Ò½ 306 ר˶һ־Ը b Çø
ÒѾÓÐ9È˻ظ´














»Ø¸´´ËÂ¥